Karl Piirimae Represents Global Pharmaceuticals Company in Acquisition of Immunotherapy Manufacturing Facility
Karl Piirimae (Partner, New Jersey and New York) represented a global pharmaceuticals company in the real estate aspects of its acquisition of an immunotherapy manufacturing facility in New Jersey from Dendreon Corporation. Working with the client's worldwide oncology group and its facilities management group in New Jersey, Karl handled fast-track negotiations to obtain landlord consent to the assignment of the lease. He also negotiated key amendments to the lease to permit the use of the facility to support clinical and commercial production of potential new products and personalized cell therapies. Ed Shea (Counsel, New York) advised in connection with ISRA compliance and environmental matters.
The transaction also permitted the retention of 100 jobs in New Jersey that otherwise would have been lost to the closure of the plant.
NJBiz covered the deal here.